アルコール性肝炎治療の世界市場予測・分析:コルチコステロイド、キサンチン誘導体、その他

Technavioが発行した調査報告書(IRTNTR31503)
◆英語タイトル:Alcoholic Hepatitis Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31503
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月24日
◆ページ数:114
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:APAC,Europe, MEA, North America, South America,
◆産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥318,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社の本調査レポートでは、アルコール性肝炎治療の世界市場について調べ、アルコール性肝炎治療の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、アルコール性肝炎治療の市場規模をセグメンテーション別(種類別(コルチコステロイド、キサンチン誘導体、その他)、)と地域別(APAC,Europe, MEA, North America, South America,)に分けて算出しました。Technavio社はアルコール性肝炎治療の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・アルコール性肝炎治療の市場状況
・アルコール性肝炎治療の市場規模
・アルコール性肝炎治療の市場予測
・アルコール性肝炎治療の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(コルチコステロイド、キサンチン誘導体、その他)
・アルコール性肝炎治療の顧客状況
・主要地域別市場規模:APAC,Europe, MEA, North America, South America,
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Alcoholic Hepatitis Treatment Market: About this market

Alcoholic hepatitis is inflammation of the liver, which is caused due to the heavy drinking of alcohol. Technavio’s alcoholic hepatitis treatment market analysis considers sales from different types of treatments, including corticosteroids, xanthine derivatives, and others. Our analysis also considers the sales of alcoholic hepatitis treatment in Asia, Europe, North America, and ROW. In 2018, the corticosteroids segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the development of combination therapies will play a significant role in the corticosteroids segment to maintain its market position. Also, our global alcoholic hepatitis treatment market report looks at factors such as the increasing consumption of alcohol worldwide, availability of prognostic models for alcoholic hepatitis, and high market penetration of corticosteroids and off-label therapies. However, lack of therapies to treat severe alcoholic hepatitis, side effects associated with drugs used to treat alcoholic hepatitis, and availability of alternative therapies may hamper the growth of the alcoholic hepatitis treatment industry over the forecast period.

Global Alcoholic Hepatitis Treatment Market: Overview

Increasing consumption of alcohol worldwide

Heavy alcohol consumption leads to hepatic encephalopathy and high mortality rates. This has created an opportunity for vendors to launch off-label therapies and corticosteroids in the market. The increasing demand for these drugs will lead to the expansion of the global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period.

Development of novel targets and viable treatment options for the management of alcoholic hepatitis

Vendors are heavily investing in the development of novel targets and viable treatment options due to the lack of effective treatments for severe alcoholic hepatitis. Also, certain novel drugs developed by them are under clinical trials. This further creates growth opportunities for vendors, which is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global alcoholic hepatitis treatment market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global alcoholic hepatitis treatment market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alcoholic hepatitis treatment manufacturers, that include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd.

Also, the alcoholic hepatitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Corticosteroids – Market size and forecast 2018-2023

Xanthine derivatives – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Development of combination therapies to treat severe alcoholic hepatitis

Development of novel targets and viable treatment options for

management of alcoholic hepatitis

Research for development of drugs that act against alcohol dependence

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Apotex Inc.

Gilead Sciences Inc.

Johnson & Johnson Services Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global metabolic disorder therapeutics market

Exhibit 02: Segments of global metabolic disorder therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Type – Market share 2018-2023 (%)

Exhibit 18: Comparison by type

Exhibit 19: Corticosteroids – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Corticosteroids – Year-over-year growth 2019-2023 (%)

Exhibit 21: Xanthine derivatives – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Xanthine derivatives – Year-over-year growth 2019-2023 (%)

Exhibit 23: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Others – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by type

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: North America – Year-over-year growth 2019-2023 (%)

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 37: Key leading countries

Exhibit 38: Market opportunity

Exhibit 39: Impact of drivers and challenges

Exhibit 40: Novel drugs under development for alcoholic hepatitis

Exhibit 41: Vendor landscape

Exhibit 42: Landscape disruption

Exhibit 43: Vendors covered

Exhibit 44: Vendor classification

Exhibit 45: Market positioning of vendors

Exhibit 46: Apotex Inc. – Vendor overview

Exhibit 47: Apotex Inc. – Key offerings

Exhibit 48: Gilead Sciences Inc. – Vendor overview

Exhibit 49: Gilead Sciences Inc. – Business segments

Exhibit 50: Gilead Sciences Inc. – Organizational developments

Exhibit 51: Gilead Sciences Inc. – Geographic focus

Exhibit 52: Gilead Sciences Inc. – Key offerings

Exhibit 53: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 54: Johnson & Johnson Services, Inc. – Business segments

Exhibit 55: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 56: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 57: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 58: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 59: Novartis AG – Vendor overview

Exhibit 60: Novartis AG – Business segments

Exhibit 61: Novartis AG – Organizational developments

Exhibit 62: Novartis AG – Geographic focus

Exhibit 63: Novartis AG – Segment focus

Exhibit 64: Novartis AG – Key offerings

Exhibit 65: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 66: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 67: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 68: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 69: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 70: Validation techniques employed for market sizing

Exhibit 71: Definition of market positioning of vendors



【掲載企業】

Apotex Inc.
Gilead Sciences Inc.
Johnson & Johnson Services Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アルコール性肝炎治療の世界市場予測・分析:コルチコステロイド、キサンチン誘導体、その他(Alcoholic Hepatitis Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆